Rhumbline Advisers Sells 3,114 Shares of REGENXBIO Inc. $RGNX

Rhumbline Advisers decreased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 4.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 71,155 shares of the biotechnology company’s stock after selling 3,114 shares during the period. Rhumbline Advisers owned approximately 0.14% of REGENXBIO worth $509,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new stake in shares of REGENXBIO during the 1st quarter valued at $35,000. Brooklyn Investment Group grew its holdings in shares of REGENXBIO by 163.7% in the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 3,466 shares during the period. Pallas Capital Advisors LLC acquired a new position in shares of REGENXBIO in the 1st quarter valued at $74,000. Entropy Technologies LP acquired a new position in shares of REGENXBIO in the 1st quarter valued at $107,000. Finally, GAMMA Investing LLC grew its holdings in shares of REGENXBIO by 372.1% in the 1st quarter. GAMMA Investing LLC now owns 16,188 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 12,759 shares during the period. Institutional investors own 88.08% of the company’s stock.

Insiders Place Their Bets

In other REGENXBIO news, CEO Curran Simpson sold 7,734 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $10.02, for a total value of $77,494.68. Following the transaction, the chief executive officer directly owned 244,597 shares of the company’s stock, valued at $2,450,861.94. This represents a 3.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.79% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on RGNX shares. Chardan Capital reissued a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Monday, September 8th. Wall Street Zen lowered shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a report on Saturday, August 9th. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of REGENXBIO in a report on Monday, September 8th. Barclays decreased their price target on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, August 8th. Finally, Royal Bank Of Canada decreased their price target on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.38.

REGENXBIO Stock Down 1.4%

REGENXBIO stock opened at $8.93 on Wednesday. The stock has a market cap of $451.05 million, a P/E ratio of -2.60 and a beta of 1.17. REGENXBIO Inc. has a twelve month low of $5.03 and a twelve month high of $12.22. The company’s 50-day moving average price is $8.81 and its two-hundred day moving average price is $8.40.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. Equities analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.